SG Americas Securities LLC Lowers Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

SG Americas Securities LLC lowered its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 74.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,303 shares of the company’s stock after selling 56,985 shares during the period. SG Americas Securities LLC’s holdings in EyePoint Pharmaceuticals were worth $154,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of EyePoint Pharmaceuticals by 17.8% during the 1st quarter. Vanguard Group Inc. now owns 2,396,228 shares of the company’s stock worth $49,530,000 after buying an additional 362,168 shares during the last quarter. RA Capital Management L.P. acquired a new stake in EyePoint Pharmaceuticals during the first quarter worth about $19,401,000. Deerfield Management Company L.P. Series C increased its stake in EyePoint Pharmaceuticals by 51.4% during the second quarter. Deerfield Management Company L.P. Series C now owns 877,790 shares of the company’s stock worth $7,637,000 after acquiring an additional 298,196 shares during the last quarter. Fiera Capital Corp raised its holdings in shares of EyePoint Pharmaceuticals by 0.9% in the 2nd quarter. Fiera Capital Corp now owns 677,038 shares of the company’s stock worth $5,890,000 after purchasing an additional 5,920 shares during the period. Finally, Perceptive Advisors LLC lifted its stake in shares of EyePoint Pharmaceuticals by 8.6% in the 2nd quarter. Perceptive Advisors LLC now owns 640,274 shares of the company’s stock valued at $5,570,000 after purchasing an additional 50,628 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, June 27th. Jefferies Financial Group initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a “buy” rating and a $15.00 target price on the stock. Scotiabank assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 price target for the company. StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a research report on Saturday, September 21st. Finally, Chardan Capital restated a “buy” rating and set a $28.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Friday, June 28th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, EyePoint Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $29.00.

EyePoint Pharmaceuticals Price Performance

Shares of EYPT stock opened at $9.56 on Friday. The company’s fifty day moving average price is $8.87 and its two-hundred day moving average price is $10.75. The firm has a market capitalization of $511.65 million, a P/E ratio of -5.34 and a beta of 1.57. EyePoint Pharmaceuticals, Inc. has a 12 month low of $5.67 and a 12 month high of $30.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.03). EyePoint Pharmaceuticals had a negative return on equity of 43.24% and a negative net margin of 172.29%. The business had revenue of $9.48 million during the quarter, compared to analyst estimates of $11.61 million. On average, sell-side analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.